Cargando…
The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) commonly complicates with coagulopathy. A syndrome called Long-COVID-19 is emerging recently in COVID-19 survivors, characterized, in addition to the persistence of symptoms typical of the acute phase, by alterations in inflammatory and co...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540492/ https://www.ncbi.nlm.nih.gov/pubmed/34696334 http://dx.doi.org/10.3390/v13101904 |
_version_ | 1784589000010366976 |
---|---|
author | Acanfora, Domenico Acanfora, Chiara Ciccone, Marco Matteo Scicchitano, Pietro Bortone, Alessandro Santo Uguccioni, Massimo Casucci, Gerardo |
author_facet | Acanfora, Domenico Acanfora, Chiara Ciccone, Marco Matteo Scicchitano, Pietro Bortone, Alessandro Santo Uguccioni, Massimo Casucci, Gerardo |
author_sort | Acanfora, Domenico |
collection | PubMed |
description | Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) commonly complicates with coagulopathy. A syndrome called Long-COVID-19 is emerging recently in COVID-19 survivors, characterized, in addition to the persistence of symptoms typical of the acute phase, by alterations in inflammatory and coagulation parameters due to endothelial damage. The related disseminated intravascular coagulation (DIC) can be associated with high death rates in COVID-19 patients. It is possible to find a prothrombotic state also in Long-COVID-19. Early administration of anticoagulants in COVID-19 was suggested in order to improve patient outcomes, although exact criteria for their application were not well-established. Low-molecular-weight heparin (LMWH) was commonly adopted for counteracting DIC and venous thromboembolism (VTE), due to its pharmacodynamics and anti-inflammatory properties. However, the efficacy of anticoagulant therapy for COVID-19-associated DIC is still a matter of debate. Thrombin and Factor Xa (FXa) are well-known components of the coagulation cascade. The FXa is known to strongly promote inflammation as the consequence of increased cytokine expression. Endothelial cells and mononuclear leucocytes release cytokines, growth factors, and adhesion molecules due to thrombin activation. On the other hand, cytokines can activate coagulation. The cross-talk between coagulation and inflammation is mediated via protease-activated receptors (PARs). These receptors might become potential targets to be considered for counteracting the clinical expressions of COVID-19. SARS-CoV-2 is effectively able to activate local and circulating coagulation factors, thus inducing the generation of disseminated coagula. LMWH may be considered as the new frontier in the treatment of COVID-19 and Long-COVID-19. Indeed, direct oral anticoagulants (DOACs) may be an alternative option for both early and later treatment of COVID-19 patients due to their ability to inhibit PARs. The aim of this report was to evaluate the role of anticoagulants—and DOACs in particular in COVID-19 and Long-COVID-19 patients. We report the case of a COVID-19 patient who, after administration of enoxaparin developed DIC secondary to virosis and positivity for platelet factor 4 (PF4) and a case of Long-COVID with high residual cardiovascular risk and persistence of blood chemistry of inflammation and procoagulative state. |
format | Online Article Text |
id | pubmed-8540492 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85404922021-10-24 The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases Acanfora, Domenico Acanfora, Chiara Ciccone, Marco Matteo Scicchitano, Pietro Bortone, Alessandro Santo Uguccioni, Massimo Casucci, Gerardo Viruses Case Report Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) commonly complicates with coagulopathy. A syndrome called Long-COVID-19 is emerging recently in COVID-19 survivors, characterized, in addition to the persistence of symptoms typical of the acute phase, by alterations in inflammatory and coagulation parameters due to endothelial damage. The related disseminated intravascular coagulation (DIC) can be associated with high death rates in COVID-19 patients. It is possible to find a prothrombotic state also in Long-COVID-19. Early administration of anticoagulants in COVID-19 was suggested in order to improve patient outcomes, although exact criteria for their application were not well-established. Low-molecular-weight heparin (LMWH) was commonly adopted for counteracting DIC and venous thromboembolism (VTE), due to its pharmacodynamics and anti-inflammatory properties. However, the efficacy of anticoagulant therapy for COVID-19-associated DIC is still a matter of debate. Thrombin and Factor Xa (FXa) are well-known components of the coagulation cascade. The FXa is known to strongly promote inflammation as the consequence of increased cytokine expression. Endothelial cells and mononuclear leucocytes release cytokines, growth factors, and adhesion molecules due to thrombin activation. On the other hand, cytokines can activate coagulation. The cross-talk between coagulation and inflammation is mediated via protease-activated receptors (PARs). These receptors might become potential targets to be considered for counteracting the clinical expressions of COVID-19. SARS-CoV-2 is effectively able to activate local and circulating coagulation factors, thus inducing the generation of disseminated coagula. LMWH may be considered as the new frontier in the treatment of COVID-19 and Long-COVID-19. Indeed, direct oral anticoagulants (DOACs) may be an alternative option for both early and later treatment of COVID-19 patients due to their ability to inhibit PARs. The aim of this report was to evaluate the role of anticoagulants—and DOACs in particular in COVID-19 and Long-COVID-19 patients. We report the case of a COVID-19 patient who, after administration of enoxaparin developed DIC secondary to virosis and positivity for platelet factor 4 (PF4) and a case of Long-COVID with high residual cardiovascular risk and persistence of blood chemistry of inflammation and procoagulative state. MDPI 2021-09-23 /pmc/articles/PMC8540492/ /pubmed/34696334 http://dx.doi.org/10.3390/v13101904 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Acanfora, Domenico Acanfora, Chiara Ciccone, Marco Matteo Scicchitano, Pietro Bortone, Alessandro Santo Uguccioni, Massimo Casucci, Gerardo The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases |
title | The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases |
title_full | The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases |
title_fullStr | The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases |
title_full_unstemmed | The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases |
title_short | The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases |
title_sort | cross-talk between thrombosis and inflammatory storm in acute and long-covid-19: therapeutic targets and clinical cases |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540492/ https://www.ncbi.nlm.nih.gov/pubmed/34696334 http://dx.doi.org/10.3390/v13101904 |
work_keys_str_mv | AT acanforadomenico thecrosstalkbetweenthrombosisandinflammatorystorminacuteandlongcovid19therapeutictargetsandclinicalcases AT acanforachiara thecrosstalkbetweenthrombosisandinflammatorystorminacuteandlongcovid19therapeutictargetsandclinicalcases AT cicconemarcomatteo thecrosstalkbetweenthrombosisandinflammatorystorminacuteandlongcovid19therapeutictargetsandclinicalcases AT scicchitanopietro thecrosstalkbetweenthrombosisandinflammatorystorminacuteandlongcovid19therapeutictargetsandclinicalcases AT bortonealessandrosanto thecrosstalkbetweenthrombosisandinflammatorystorminacuteandlongcovid19therapeutictargetsandclinicalcases AT uguccionimassimo thecrosstalkbetweenthrombosisandinflammatorystorminacuteandlongcovid19therapeutictargetsandclinicalcases AT casuccigerardo thecrosstalkbetweenthrombosisandinflammatorystorminacuteandlongcovid19therapeutictargetsandclinicalcases AT acanforadomenico crosstalkbetweenthrombosisandinflammatorystorminacuteandlongcovid19therapeutictargetsandclinicalcases AT acanforachiara crosstalkbetweenthrombosisandinflammatorystorminacuteandlongcovid19therapeutictargetsandclinicalcases AT cicconemarcomatteo crosstalkbetweenthrombosisandinflammatorystorminacuteandlongcovid19therapeutictargetsandclinicalcases AT scicchitanopietro crosstalkbetweenthrombosisandinflammatorystorminacuteandlongcovid19therapeutictargetsandclinicalcases AT bortonealessandrosanto crosstalkbetweenthrombosisandinflammatorystorminacuteandlongcovid19therapeutictargetsandclinicalcases AT uguccionimassimo crosstalkbetweenthrombosisandinflammatorystorminacuteandlongcovid19therapeutictargetsandclinicalcases AT casuccigerardo crosstalkbetweenthrombosisandinflammatorystorminacuteandlongcovid19therapeutictargetsandclinicalcases |